Clinical Research Assistant

SHRAVANTHI MOULI

****, ******* *** ***, ************, IN 46237 334-***-**** *************@*****.*** EDUCATION

Doctor of Philosophy (Ph.D.), Pharmacology, Aug 2016, Auburn University, Auburn, AL o Dissertation: ‘The Role of Frataxin in Doxorubicin Mediated Cardiac Hypertrophy’

Master of Science (M.Sc.), Pharmaceutical Science, Aug 2011, Leeds University, Leeds, UK

Master of Science, (M.Sc.) Biotechnology, Apr 2009, Madras University, India SOFTWARE/ IT SKILLS

PRISM-GraphPad, Image J, Minitab, MS Office (Word, Excel, PowerPoint) RESEARCH EXPERIENCE

Indiana University School of Medicine

Postdoctoral Research Fellow Nov 2017-Jan 2018

Cell culture and maintenance of HEK293, MEL 526 cell lines

Seahorse XFe 24 Extracellular Flux Analyzer – Measurement of mitochondrial respiration

Troubleshooting/problem solving skills.

Nucleic Acid Based Drugs, (NUBAD, LLC), SC

Research Scientist Jan 2017-Mar 2017

Designed experiments, screened in-house pharmaceuticals synthesized at NUBAD for anti-tumor activity in mammalian cells

Performed cytotoxicity assays of NUBAD-synthesized selective aminoglycoside derivatives in cancer cell lines

Mammalian cell culture including passaging and transfecting HEK293, CHO and prostate cancer cell lines

(ACHN, UO-31, LNCaP), cytotoxicity/cell viability assays: MTT, CCK8, SRB

Microplate handling for high throughput screening for cell based assays

Good working knowledge of ICH GCP principles and ICH compliant regulatory submissions - IND, NDA, BLA, GMP, ISO and FDA regulatory guidelines.

Auburn University, Auburn, AL

Research Assistant Aug 2012-Aug 2016

The Role of Frataxin (FXN) in Doxorubicin Mediated Cardiac Hypertrophy

Initiated new research in lab by investigating the role of novel protein FXN in the heart upon chemotherapy doxorubicin (DOX) exposure, in cell cultures and in adult mice hearts PPARδ mediated protection against doxorubicin cardiotoxicity requires Frataxin

Demonstrated that PPARδ transcriptionally regulates FXN and improves FXN levels in heart upon DOX treatment

Mammalian cell culture including passaging and transfecting adult/neonatal cardiomyocytes.

Construction of stable cell line-FXN knockdown and overexpression in H9C2 cardiomyocytes

qPCR, DNA/RNA extraction, PCR, qRT-PCR, western blot analysis, immunoprecipitation, pull down assays (V5 tag), luciferase assay and metabolic bioassay. Analyzed data by one way ANOVA followed by Tukey’s post hoc analysis

PUBLICATIONS

1. Shravanthi Mouli, Gayani Nanayakkara, Xiayou Fu, Abdullah AlAsmari, Haitham Eldoumani, Robert D Arnold and Rajesh Amin. “The Role of Frataxin In Doxorubicin Mediated Cardiac Hypertrophy”, American Journal of Physiology- Heart and Circulatory Physiology, 2015 2. Gayani Nanayakkara, Abdullah AlAsmari, Shravanthi Mouli, Haitham Eldoumani and Rajesh Amin,

“Cardioprotective HIF-1α- Frataxin Signaling Against Ischemic Reperfusion Injury”. American Journal of Physiology – Heart and Circulatory Physiology, 2015 3. Jeong Yeon Kang, Mathew Eggert, Shravanthi Mouli, Ibrahim Aljuffali, Xiaoyu Fu, Ben Nie, Amy Sheil, Sheldon May, Robert D Arnold. “Pharmacokinetics, Antitumor and Cardioprotective Effects Of Liposome- Encapsulated Phenylaminoethyl Selenide In Human prostate Cancer Rodent Models” Journal of Pharmaceutical Research, March 2014

Contact this candidate